Baldrige Asset Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Baldrige Asset Management’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$0	Hold	37	–	–	﹤0.01%	408
2022 Q4	$1K	Hold	37	–	–	﹤0.01%	295
2022 Q3	$1K	Hold	37	–	–	﹤0.01%	288
2022 Q2	$1K	Hold	37	–	–	﹤0.01%	293
2022 Q1	$1K	Hold	37	–	–	﹤0.01%	304
2021 Q4	$1K	Hold	37	–	–	﹤0.01%	318
2021 Q3	$1K	Hold	37	–	–	﹤0.01%	345
2021 Q2	$1K	Buy	+37	New	+$1.12K	﹤0.01%	342

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Baldrige Asset Management's CNCR Position: Q1 2023 in Review

Baldrige Asset Management held its ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) position steady in Q1 2023 at 37 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #408.

Baldrige Asset Management first reported a position in CNCR in Q2 2021 and has held it in 8 quarters since. The position peaked at $1K in Q4 2022. 15 funds tracked by Wall St. Rank hold CNCR as of Q1 2023.

Baldrige Asset Management held 37 shares of ETF Series Solutions Trust Range Cancer Therapeutics ETF worth $0 as of Q1 2023.
Baldrige Asset Management left its ETF Series Solutions Trust Range Cancer Therapeutics ETF share count unchanged in Q1 2023.
ETF Series Solutions Trust Range Cancer Therapeutics ETF made up ﹤0.01% of Baldrige Asset Management's portfolio in Q1 2023, its #408 holding.
Baldrige Asset Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2021 and has held it in 8 quarters since.
Baldrige Asset Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $1K in Q4 2022.
15 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2023.

Based on Baldrige Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.